Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain XLRN message board posts where the ticker symbol XLRN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest XLRN SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000080255-18-002545 (34 Act)  Size: 6 KB
2018-02-14 005-87630
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-002019 Size: 4 KB
2018-02-13
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001179110-18-002018 Size: 6 KB
2018-02-13
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-000990 (34 Act)  Size: 9 KB
2018-02-13 005-87630
18599513
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-18-002554 (34 Act)  Size: 45 KB
2018-02-08 005-87630
18583473
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000215457-18-002249 (34 Act)  Size: 13 KB
2018-01-23 005-87630
18541948
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-000920 Size: 8 KB
2018-01-17
8-K  Documents Current report, items 7.01, 8.01, and 9.01
Acc-no: 0001280600-18-000004 (34 Act)  Size: 3 MB
2018-01-08 001-36065
18515041
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-000549 Size: 6 KB
2018-01-04
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-000548 Size: 5 KB
2018-01-04
More XLRN SEC Filings


Related news from
Tue, 20 Feb 2018
12:00:00 +0000
Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018
Acceleron Pharma Inc. today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.m. EST to discuss its fourth quarter and full year 2017 operating and financial results.
Thu, 08 Feb 2018
21:01:00 +0000
Acceleron Announces Appointment of Chief Commercial Officer
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of commercial industry leader, Sujay Kango as Chief Commercial Officer .
Wed, 31 Jan 2018
12:00:00 +0000
Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Acceleron Pharma Inc.  , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018 at 3:30 p.m.
Tue, 23 Jan 2018
13:00:00 +0000
Celgene's Investments Are Soaring
The biotech Goliath's investment portfolio is paying off.
Wed, 17 Jan 2018
13:20:00 +0000
Consolidated Research: 2018 Summary Expectations for Eclipse Resources, Unit, Post, Acceleron Pharma, SELECT EGY SVCS, and Concho Resources — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eclipse ...
Mon, 08 Jan 2018
16:05:00 +0000
Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced positive preliminary results for the first two cohorts in Part 1 of the Phase 2 clinical trial with ACE-083 in patients with facioscapulohumeral dystrophy , a rare genetic muscle disorder that results in progressive focal muscle loss ...
Wed, 03 Jan 2018
12:00:00 +0000
Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the planned retirement of Executive Vice President and Chief Medical Officer Matthew L.
Tue, 02 Jan 2018
12:00:00 +0000
Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will present at the 36th Annual J.P.
Fri, 22 Dec 2017
08:00:00 +0000
Acceleron Pharma Joins Rank Of Stocks With RS Ratings Over 90
A Relative Strength Rating upgrade for Acceleron Pharma shows improving technical performance.
Thu, 21 Dec 2017
08:00:00 +0000
Acceleron Pharma Hits 80-Plus Relative Strength Rating Benchmark
Acceleron Pharma shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.
Tue, 19 Dec 2017
08:00:00 +0000
Stocks Showing Improved Relative Strength: Acceleron Pharma
Acceleron Pharma shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Tue, 12 Dec 2017
08:00:00 +0000
Acceleron Pharma Sees RS Rating Climb To 74
Acceleron Pharma shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Sun, 10 Dec 2017
14:00:00 +0000
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing Phase 2 trials with luspatercept in patients with lower-risk myelodysplastic syndromes at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.
Thu, 07 Dec 2017
21:28:28 +0000
5 Health Care Stocks Gurus Are Buying
Gurus are investing in these popular stocks
Tue, 05 Dec 2017
12:00:00 +0000
Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition
Acceleron Pharma Inc. will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.m. EST to review highlights from its Phase 2 clinical presentations at the 59th American Society of Hematology Annual Meeting and Exposition taking place December 9-12, 2017 in Atlanta, Georgia.
Mon, 20 Nov 2017
12:26:00 +0000
Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : November 20, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Acceleron Pharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more <b>(Read more...)</b>
Thu, 16 Nov 2017
12:10:00 +0000
Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195
Research Desk Line-up: Acceleron Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
Wed, 15 Nov 2017
21:01:00 +0000
Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire
Acceleron Pharma Inc. today announced the appointment of the experienced biopharmaceutical executive, Karen Smith, M.D., Ph.D., to its board of directors and the departure of Terrance McGuire, effective November 15, 2017.
Tue, 14 Nov 2017
21:01:00 +0000
Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced new preclinical results with sotatercept in pulmonary arterial hypertension during an oral presentation at the American Heart Association 2017 Scientific Sessions in Anaheim, California.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is a great group of value seeking investors, who are most generous in sharing their research, news, business expertise, and investment experience. It is an invaluable resource, and brings many 'lessons learned' to the group." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards